Letter
to Shareholders from 4Cable TV International, Inc.
January 5, 2024 --
InvestorsHub NewsWire --
Dear Shareholders,
I trust this letter finds
you in good health and high spirits after the Holidays and hope
that you are ready to move forward into the new year as much as we
are. It is with great enthusiasm that I reach out to provide
you with updates and insights into the exciting developments at our
company, soon to be known as Category V Biotech, Inc.
Name Change
Progress: We are pleased to inform you that we have
submitted all necessary documentation for the impending change of
our company's name to Category V Biotech, Inc. Currently, we
eagerly await FINRA's approval, a crucial step in our strategic
rebranding process. The transition to Category V Biotech, Inc.
signifies our evolution and commitment to a future where innovation
and biotechnology will play a central role.
Financial Audit
Initiatives: In our pursuit of excellence, we are actively
seeking quotes from PCAOB accounting firms to conduct a
comprehensive financial audit. This step is integral to
ensuring transparency, accountability, and the reliability of our
financial information. As we embark on this process, we remain
dedicated to upholding the highest standards in financial
reporting.
Resilience After the
CE "Hurricane" Impact: Our company has weathered the
challenges posed by a Category V Hurricane in the form of a Caveat
Emptor, and we are resolute in our determination to rebuild and
thrive. Our core vision remains steadfast as we focus on
becoming a prominent player in the cannabis industry. Our
objectives include cannabis cultivation, the development of
cannabis facilities for craft growers, and venturing into the
realms of food, beverages, and functional mushrooms where we
believe the future is going.
Future Strategies and
Predictions: Drawing inspiration from the insightful
predictions of Andrew Kaye, Chief Commercial Officer of Sweet Leaf
Madison Capital, as he wrote on his predictions for the industry in
2024, (https://mjbizdaily.com/these-trends-could-impact-cannabis-market-in-2024/)
we are aligning our growth strategy with the anticipated trends in
the cannabis industry. As we work on our progress in the East
Coast, we are poised to capitalize on the expansion of regulated
marijuana markets and the potential rescheduling of marijuana from
Schedule 1 to Schedule 3, which could bring about positive changes
for cannabis companies.
Business Tiers and
Requirements: Our commitment to scientific innovation
remains unwavering, as we aspire to create Category V products with
the potential to address and cure diseases. Our business
tiers encompass cultivation, product creation through scientific
research, and the establishment of craft cultivation facilities. To
achieve these goals, we emphasize the importance of scientific data
gathering, analysis, and the implementation of Good Agricultural
Practices in all of our companies' branches.
Facing Financing
Challenges with Optimism: While we acknowledge the
challenges presented by financing constraints, we want to assure
you that we are actively exploring opportunities to raise
capital. A forthcoming capital raise will empower us to
pursue our objectives with vigor, driving innovation and growth in
the evolving cannabis landscape.
In closing, I want to
express my sincere gratitude for your continued support. We remain
dedicated to our vision, and with your backing, we are confident in
our ability to navigate challenges and emerge stronger than
ever.
Thank you for being an
integral part of the soon to be named company Category V Biotech,
Inc. journey.
Warm regards,
Michael Feldenkrais CEO
